Lilly posts new Heart-2 data for one-time gene-editing therapy: full analysis
Eli Lilly has posted updated Phase 1b Heart-2 results for VERVE-102, a one-time investigational gene-editing treatment for hypercholesterolemia, with data suggesting a single infusion can durably reduce both PCSK9 and LDL cholesterol. According to Lilly, the therapy lowered PCSK9 by up to 88% and LDL-C by up to 62% in adults at high cardiovascular risk, extending earlier proof-of-concept findings for the program. The dataset was presented at the 2026 European Atherosclerosis Society Congress and simultaneously published in The New England Journal of Medicine. (investor.lilly.com)
The update builds on earlier Heart-2 data disclosed by Verve Therapeutics in April 2025, when the first 14 treated participants showed dose-dependent LDL-C reductions, including a mean 53% drop and a maximum 69% reduction in the 0.6 mg/kg cohort. VERVE-102 followed Verve’s earlier PCSK9 program, VERVE-101, and was designed with a GalNAc-lipid nanoparticle delivery approach intended to improve liver targeting by using either LDL receptor or asialoglycoprotein receptor uptake. Lilly’s interest in the platform culminated in its 2025 acquisition of Verve, giving the larger company control of the cardiovascular gene-editing pipeline. (vervetx.gcs-web.com)
In the current Heart-2 readout, Lilly said 35 participants with heterozygous familial hypercholesterolemia and/or premature coronary artery disease had been treated across escalating dose cohorts. VERVE-102 consists of messenger RNA encoding an adenine base editor plus a guide RNA targeting PCSK9, packaged in a GalNAc-containing lipid nanoparticle. The goal is not repeated pharmacologic suppression, but durable inactivation of the PCSK9 gene in the liver after a single infusion. Lilly described the reductions in circulating PCSK9 and LDL-C as dose-dependent and sustained, with follow-up extending as long as 18 months for some participants. (nejm.org)
Industry coverage framed the results as an encouraging early validation of Lilly’s bet on cardiovascular gene editing, while also underscoring unanswered questions about patient selection, long-term safety, and commercial positioning against established lipid-lowering drugs. Reporting from STAT noted Lilly’s ambition to move beyond chronic treatment toward a one-time intervention model, and BioPharma Dive similarly described the data as an early-stage success that could support advancement into Phase 2. Fierce Biotech highlighted a central debate for the field: which patients will be appropriate candidates for an irreversible gene-editing therapy when effective chronic options already exist. (statnews.com)
Why it matters: For veterinary professionals, this isn’t a practice-changing animal health development, but it is a meaningful translational signal. Gene editing has often been discussed in abstract terms; Heart-2 offers a concrete example of in vivo base editing producing durable biologic effects after a single administration in a chronic disease setting. That matters for anyone tracking where biotechnology platforms may head next, including in comparative medicine, inherited disease research, and future companion animal therapeutics. It also reinforces that delivery technology, not just editing chemistry, is becoming a differentiator in whether these approaches can work safely and predictably in living patients. (nejm.org)
There are, of course, important limits. Heart-2 remains an early-stage, open-label dose-escalation study in a small number of human participants, and longer follow-up will be essential to understand durability, off-target effects, liver safety, immunologic issues, and whether LDL lowering translates into fewer cardiovascular events. For veterinarians reading across sectors, the bigger lesson may be less about cholesterol specifically and more about the maturation of one-time genomic medicines as a development class. (nejm.org)
What to watch: Lilly has said it intends to begin a Phase 2 study by the end of 2026, so the next milestones are likely to include fuller safety follow-up, more clarity on target patient populations, and eventual evidence on whether durable gene editing can compete with or complement lifelong lipid-lowering therapy. (investor.lilly.com)